Densitas, a global leader in artificial intelligence solutions for breast cancer screening, has forged a strategic partnership with CancerIQ, a precision cancer prevention platform. This collaboration marks an expansion of Densitas' capabilities by incorporating CancerIQ's Tyrer-Cuzick 8 risk calculator, care management tools, and patient activation features.

In this joint effort, Densitas will seamlessly integrate CancerIQ's Tyrer-Cuzick 8 risk calculator into its mammography quality AI platform. This integration empowers healthcare professionals to assess patient lifetime risk and current breast health, create risk-based care plans, and offer vital patient education and navigation support. Densitas' advanced AI-driven mammography quality assurance platform consists of intelliMammo® and intelliMaven™, utilizing deep learning and machine learning algorithms for evaluating clinical image quality and breast density, thereby enhancing analytics and workflow functions.

By combining intelliMammo® and intelliMaven™, Densitas provides a comprehensive solution that not only boosts operational efficiency and elevates mammography quality but also instills greater clinical confidence. The platform ensures compliance with the FDA's Mammography Quality Standards Act (MQSA) EQUIP and adheres to the American College of Radiology's standards. Notably, intelliMammo® significantly reduces error rates in clinical image quality and facilitates rapid compliance with MQSA EQUIP and ACR accreditation requirements.

This strategic partnership strategically positions Densitas, alongside CancerIQ, to assist care providers in achieving and surpassing FDA MQSA EQUIP compliance, ACR Accreditation, and the 2024 Accreditation requirements outlined by the National Accreditation Program for Breast Centers (NAPBC). The integrated product suites deliver a holistic solution for care providers, offering a robust platform for insightful, data-driven analyses of mammography quality and patient risk profiles.

Source: prnewswire.com